会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • COMPOSITION AND METHOD FOR THE TREATMENT OF TAUOPATHIES
    • 用于治疗TAUOPATHIES的组合物和方法
    • US20120149685A1
    • 2012-06-14
    • US13185921
    • 2011-07-19
    • Hanno RODER
    • Hanno RODER
    • A61K31/553A61P25/28A61P25/16C07D498/22
    • A61K31/553
    • The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurode-generative and/or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.
    • 本发明涉及通式(1)的特定吲哚并咔唑化合物或其药学上可接受的盐的用途,用于制备用于预防或治疗由以下物质驱动的神经发生和/或痴呆疾病的药物组合物: 微管相关性tau的分子病理学如阿尔茨海默病,额叶痴呆,皮克病,帕金森病与痴呆,皮质基底变性,嗜ilic性颗粒病或核核性麻痹。 还公开了治疗或预防这种疾病的方法。 此外,描述了用于鉴定神经原纤维变性的有效抑制剂的方法,以及用于确定用于治疗以神经原纤维病理学为特征的病症的PHF型tau高度磷酸化的抑制剂的适当剂量的方法。
    • 2. 发明申请
    • Composition and Method for the Treatment of Tauopathies
    • 组合和治疗Tauopathies的方法
    • US20070232584A1
    • 2007-10-04
    • US11597771
    • 2005-05-26
    • Hanno Roder
    • Hanno Roder
    • A61K31/551A61K31/553A61P25/16A61P25/28C07D273/06C12Q1/18G01N33/15G01N33/53
    • A61K31/553
    • The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurode-generative and/or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.
    • 本发明涉及通式(1)的特定吲哚并咔唑化合物或其药学上可接受的盐的用途,用于制备用于预防或治疗由以下物质驱动的神经发生和/或痴呆疾病的药物组合物: 微管相关性tau的分子病理学如阿尔茨海默氏病,额叶痴呆,皮克病,帕金森病与痴呆,皮质基底变性,嗜ilic性颗粒病或核核性麻痹。 还公开了治疗或预防这种疾病的方法。 此外,描述了用于鉴定神经原纤维变性的有效抑制剂的方法,以及用于确定用于治疗以神经原纤维病理学为特征的病症的PHF型tau高度磷酸化的抑制剂的适当剂量的方法。
    • 10. 发明授权
    • Composition and method for the treatment of tauopathies
    • 组合物和治疗tau蛋白病的方法
    • US08003631B2
    • 2011-08-23
    • US11597771
    • 2005-05-26
    • Hanno Roder
    • Hanno Roder
    • A61K31/33A61K31/41
    • A61K31/553
    • The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurodegenerative and/or dementing illness driven by the molecular pathology of microtubule-associate tau such as Alzheimer's disease, frontal lobe dementia, Pick's disease, Parkinson disease with dementia, corticobasal degeneration, argyrophilic grains disease, or supranuclear palsy. A method for treating or preventing such illnesses is also disclosed. Furthermore, methods for the identification of efficacious inhibitors of neurofibrillary degeneration, and methods for the determination of an appropriate dosage of an inhibitor of the PHF-type tau hyperphosphorylation for the treatment of a condition characterized by neurofibrillary pathology are described.
    • 本发明涉及通式(1)的特定吲哚并咔唑化合物或其药学上可接受的盐在制备用于预防或治疗由分子驱动的神经变性和/或蜕皮疾病的药物组合物中的用途 微管相关性tau的病理学如阿尔茨海默病,额叶痴呆,皮克病,帕金森病与痴呆,皮质基底变性,嗜酸粒细胞病或核核性麻痹。 还公开了治疗或预防这种疾病的方法。 此外,描述了用于鉴定神经原纤维变性的有效抑制剂的方法,以及用于确定用于治疗以神经原纤维病理学为特征的病症的PHF型tau高度磷酸化的抑制剂的适当剂量的方法。